AH-001
/ AnHorn Medicines
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 16, 2025
Inactivation of RhoA for Hypertension Treatment Through the TRPV4-RhoA-RhoGDI1 Axis.
(PubMed, Circulation)
- "TRPV4 and RhoGDI1 knockdown attenuated AH001's inhibition of VSMC contraction and phenotypic switching to myofibroblasts. This study revealed a novel mode of RhoA signaling inhibition targeting the TRPV4-RhoA-RhoGDI1 axis, offering new insights for future antihypertensive drug development and proposing innovative strategies for targeting challenging Rho GTPases."
Journal • Cardiovascular • Hypertension • GDI1 • MRTFA • RHOA
April 15, 2025
Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration
(clinicaltrials.gov)
- P1 | N=64 | Recruiting | Sponsor: AnHorn Medicines Co. Ltd.
New P1 trial • Alopecia • Dermatology • Immunology
1 to 2
Of
2
Go to page
1